EcoDrugPlus

Neuropeptide Y Receptor Y2, Like

Ensembl ID : ENSLCRG00005017240
Gene Symbol: NPY2RL
4 Cross references
176 Possible Orthologues:

Neurotensin Receptor 1

Ensembl ID : ENSLCRG00005011716
Gene Symbol: NTSR1
3 Cross references
202 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 2

Ensembl ID : ENSLCRG00005012194
Gene Symbol: NTRK2
3 Cross references
207 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSLCRG00005016786
Gene Symbol: NTRK3
3 Cross references
192 Possible Orthologues:

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSLCRG00005014607
Gene Symbol: NTRK3
3 Cross references
202 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 1

Ensembl ID : ENSLCRG00005002543
Gene Symbol: NTRK1
3 Cross references
199 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 2b

Ensembl ID : ENSLCRG00005016556
Gene Symbol: NTRK2B
3 Cross references
207 Possible Orthologues:

Nfe2 Like Bzip Transcription Factor 2a

Ensembl ID : ENSLCRG00005019184
Gene Symbol: NFE2L2A
3 Cross references
216 Possible Orthologues:

Nicastrin

Ensembl ID : ENSLCRG00005006224
Gene Symbol: NCSTN
3 Cross references
203 Possible Orthologues:

Nicotinamide Phosphoribosyltransferase 1

Ensembl ID : ENSLCRG00005011507
Gene Symbol: NAMPT1
2 Cross references
225 Possible Orthologues:

Nischarin

Ensembl ID : ENSLCRG00005019701
Gene Symbol: NISCH
3 Cross references
208 Possible Orthologues:

Notch Receptor 1a

Ensembl ID : ENSLCRG00005018363
Gene Symbol: NOTCH1A
3 Cross references
196 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).